News Coverage from ACC 2024: Ninerafaxstat Shows Promise in Phase 2 IMPROVE-HCM Trial for Nonobstructive HCM
Data from the phase 2 IMPROVE-HCM trial suggest ninerafaxstat, a novel cardiac mitotrope, was well-tolerated and improved symptom burden among patients with nonobstructive hypertrophic cardiomyopathy (HCM).
The data, which were presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, indicate use of the agent was associated with greater ventilatory efficiency than placebo therapy at 12 weeks, with no drug-related serious adverse events reported in the trial.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
